Cargando…
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma
PURPOSE: CD19 is a cell surface protein that is found on both healthy and malignant B cells. Accordingly, it has become an important target for novel treatments for non-Hodgkin lymphomas and B-cell leukaemia. Three anti-CD19 monoclonal antibodies with distinct mechanisms of action have been develope...
Autores principales: | Zinzani, Pier Luigi, Minotti, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752543/ https://www.ncbi.nlm.nih.gov/pubmed/34741682 http://dx.doi.org/10.1007/s00432-021-03833-x |
Ejemplares similares
-
Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014) -
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019) -
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020) -
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell
Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020) -
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)